Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 44

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 44
---
AN Phase 3 clinical program (70% weighting), advancing atacicept manufacturing development for commercial readiness (20% weighting), and increasing awareness of BAFF-APRIL in disease pathophysiology and clinical data (10% weighting). In December 2024, the Compensation Committee reviewed the Company’s achievements against our 2024 corporate goals, including exceeding atacicept advancement goals related to fundraising and enrollment. Based on this review, the Compensation Committee recommended that the Board determine, and the Board subsequently approved payment of the cash incentives at 120% of target level based on the Company’s level of achievement of such metrics. Mr. Carter was not eligible for an annual cash incentive for 2024 pursuant to the terms of his offer letter. As a result, our named executive officers were awarded the following cash incentive payments for 2024:

| Name                   |     |    2024 Cash 
    Incentive 
 Compensation |
| Marshall Fordyce, M.D. |     |     $409,200 |
| Jason Carter(1)        |     |           $— |
| Robert Brenner, M.D.   |     |     $229,138 |

| (1) | Mr. Carter commenced employment with us in November 2024 and was not eligible for an annual cash incentive for 2024 pursuant to the terms of his offer letter. |

29

TABLE OF CONTENTS

Mr. Carter and Dr. Brenner each received a sign-on bonus in connection with the commencement of their respective employment with the Company – these amounts are reflected in the “Bonus” column in the Summary Compensation Table below. Equity Compensation We use equity awards to motivate our executive officers, including the named executive officers, to increase the long-term value of our common stock and, thereby, to align the interests of our executive officers with those of our stockholders. These equity awards are intended to further our success by ensuring that sustainable value creation is a key factor in our executive officers’ management of our business. The size and form of these equity awards are determined by the Compensation Committee in its discretion. As described below, in 2024, we granted equity awards in the form of stock options and RSUs to our executive officers as part of our long-term incentive compensation program. The target vehicle mix for our executive officers for 2024 was 65% options and 35% RSUs, a shift from 100% options prior to 2024, reflecting changes to our stock price and our goal of managing dilution